PO.BCS01.11 · 生物信息与计算
一种用于预测和缓解伪影变异以检测分子残留病灶的机器学习方法
A machine learning approach to predict and mitigate artifact variants for molecular residual disease detection
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肿瘤指导的分子残留病灶(MRD)检测需要从组织全基因组测序(WGS)中去除伪影,这些伪影即使在健康供者(HD)中也可能导致血浆中的假阳性判读。为解决这一问题,我们开发了一个机器学习框架,用于对组织变异的可靠性进行评分,从而提高组织指导的MRD检测的特异性和敏感性。我们使用了来自47例肿瘤及配对正常(T&MN)样本的回顾性WGS数据,涵盖多种不同的癌症类型。通过来自多个变异检出工具的共识判读策略识别体细胞单核苷酸变异(SNV)。我们从每个检出工具中提取了与信号量和信号质量相关的变异特征,随后又工程化构建了额外特征以刻画链偏倚、变异特异性及位点特异性特征。为生成训练标签,我们在配对患者血浆和107份HD血浆中评估了SNV。在HD血浆样本中平均VAF较高的变异被标记为可能的伪影(约16k个),而在配对患者血浆中VAF较高的变异被标记为真实肿瘤变异(约187k个)。随后使用17个信息量高、彼此不相关的特征训练了一个极端随机树(extremely randomized trees)模型。通过计算受试者工作特征(ROC)分析下的曲线下面积(AUC)来衡量模型性能。我们的模型区分真实肿瘤变异与可能伪影的交叉验证ROC AUC为0.94,平均精度为0.99。来自组织的关键预测特征包括肿瘤VAF、突变等位基因计数以及读段方向质量指标。在每例患者中,模型衍生的置信度评分与HD血浆样本中的平均VAF呈现强负相关(中位Spearman ρ = -0.30),优于既往方法(中位ρ = -0.17)。这项工作提供了一个数据驱动的框架,可根据组织变异是伪影的可能性对其进行系统排序和过滤。通过增强组织样本中突变判读的可靠性,该方法可提高组织指导的MRD检测的准确性。
查看英文原文 English abstract
Tumor-informed molecular residual disease (MRD) detection requires removal of artifacts from tissue whole-genome sequencing (WGS), which can cause false positive calls in plasma, even in healthy donors (HDs). To address this, we developed a machine-learning framework to score the reliability of tissue variants, thereby improving the specificity and sensitivity of tissue-informed MRD detection. We used retrospective WGS data from 47 tumor and matched normal (T&MN) samples across a diverse set of cancer types. Somatic single nucleotide variants (SNV) were identified via a consensus calling strategy from multiple variant callers. We extracted variant features from each caller relating to signal amount and quality, and subsequently engineered additional features to qualify strand bias, variant- and locus-specific characteristics. To generate training labels, SNV were evaluated in matched patient plasma and 107 HD plasmas. Variants with high mean VAF across the HD plasma samples were labeled as likely artifacts (~16k), while those with high VAF in the matched patient plasma were labeled as true tumor variants (~187k). An extremely randomized trees model was then trained using 17 informative, uncorrelated features. Model performance was measured by calculating the area under the curve (AUC) from a receiver operating characteristic (ROC) analysis. Our model distinguished true tumor variants from likely artifacts with a cross-validated ROC AUC of 0.94 and an average precision of 0.99. Key predictive features from the tissue included tumor VAF, mutant allele count, and a read orientation quality metric. In each patient, the model-derived confidence score demonstrated a strong and negative correlation with the mean VAF in the HD plasma samples (median Spearman ρ = -0.30), outperforming a previous method (median ρ = -0.17). This work provides a data-driven framework that systematically ranks and filters tissue variants by their likelihood of being artifacts. By enhancing the reliability of mutation calls from the tissue sample, this method can improve the accuracy of tissue-informed MRD detection.
利益披露 Disclosure
V. B. Guthrie,
Natera, Inc. Employment, Stock, Stock Option.
A. Shahpurwalla,
Natera, Inc. Employment, Stock, Stock Option.
D. Dargahi,
Natera, Inc. Employment, Stock, Stock Option.
O. Sakarya,
Natera, Inc. Employment, Stock, Stock Option.
S. Alexander,
Natera, Inc. Employment, Stock, Stock Option.
T. Wang,
Natera, Inc. Employment, Stock, Stock Option.
F. Lu,
Natera, Inc. Employment, Stock, Stock Option.
A. Hsieh,
Natera, Inc. Employment, Stock, Stock Option.
R. Ptashkin,
Natera, Inc. Employment, Stock, Stock Option.
M. Rabinowitz,
Natera, Inc. Employment, g., Board of Directors, non-salaried role), Stock, Stock Option, ), Travel, Patent, Consulting/Advisory Role.
MyOme Employment, g., Board of Directors, non-salaried role), Stock, Stock Option, ), Travel, Patent, Consulting/Advisory Role.
Marble Therapeutics Employment, g., Board of Directors, non-salaried role), Stock, Stock Option, Consulting/Advisory Role.
E. Kirkizlar,
Natera, Inc. Employment, Stock, Stock Option.
A. Zehir,
Natera, Inc. Employment, Stock, Stock Option.